Follow The Filings

ANIK Anika Therapeutics Inc.

Health Care, filed as ANIKA THERAPEUTICS INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by ANIK's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANIK insider trades
  • $264K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Gary P Fischetti Director
    Buy
    $41K 2,000 shares at $20.53 +3.8% to stake
    Traded Aug 3–4 Filed Aug 5
    ↗
  2. John B Henneman III Director
    Buy
    $73K 5,000 shares at $14.66 +10% to stake
    Traded May 1 Filed May 4
    ↗
  3. Stephen D. Griffin CEO
    Buy
    $150K 12,200 shares at $12.29 +51% to stake
    Traded Apr 30 Filed Apr 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 11 share withholdings for taxes, 11 option exercises, and 9 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
10-Q FORM 10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K FORM 10-K Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q FORM 10-Q Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $166.66M $119.91M $112.82M
Gross profit $103.09M $76M $63.81M
Gross margin * 61.9% 63.4% 56.6%
Net income -$82.67M -$56.38M -$10.88M
Net margin * -49.6% -47.0% -9.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $163.31M $113.65M $103.36M
Total non-current assets * $107.32M $89.09M $86.91M
Total assets $270.63M $202.74M $190.27M
Total current liabilities $31.06M $23.31M $21.91M
Total equity $212.26M $153.99M $143.46M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$1.79M $5.4M $11.19M
Cash from investing -$5.43M -$8.33M -$0.401M
Cash from financing -$6.32M -$12.73M -$10.55M
Net change in cash -$13.46M -$15.71M $0.322M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf